

MONITORING AND EVALUATION FOR VIRAL HEPATITIS B AND C:

RECOMMENDED INDICATORS AND FRAMEWORK

TECHNICAL REPORT

MONITORING AND EVALUATION FOR VIRAL HEPATITIS B AND C:

RECOMMENDED INDICATORS AND FRAMEWORK

TECHNICAL REPORT

WHO Library Cataloguing-in-Publication Data

Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework.

1. Hepatitis C – prevention and control. 2. Hepatitis B – prevention and control. 3. Hepatitis, Viral, Human. I. World Health Organization.

ISBN 978 92 4 151028 8

(NLM classification: WC 536)

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; Email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and layout: blossoming.it

TABLE OF CONTENTS

Acknowledgements	5
Abbreviations and acronyms	6
Terminology	7
Executive summary	8
1. Introduction	10
1.1 Purpose	10
1.2 Objectives	10
1.3 Content	10
1.4 Audience	11
1.5 Scope	11
1.6 Companion documents	11
1.7 Elimination agenda and global targets	11
2. Methods and processes	13
2.1 Incremental approach: adding to the result chain M&E framework developed for HIV and other programmes	13
2.2 Process and criteria for selecting indicators (18)	13
a. Core indicators for global and national monitoring and reporting:	13
b. Additional indicators for national-level monitoring and reporting	13
2.3 Indicator classification	14
2.4 Indicator metadata	14
3. Methodology for monitoring and evaluation of activities for viral hepatitis	15
3.1 Monitoring systems for viral hepatitis: an integrated incremental approach	15
3.2 Measurement methods and sources of data	15
3.3 Confidentiality and ethical considerations	15
4. Monitoring and evaluation indicators	16
4.1 Summary of indicators	16
4.2 Ten core indicators	17
The 10 indicators at a glance	17
Metadata for the 10 core indicators	17
4.3 Additional indicators: metadata table	26
Viral hepatitis-specific indicators	26
Indicators already formulated and/or collected through national health system or other programmes	29
5. References	32

TABLES AND FIGURES

Fig. 1: Monitoring and evaluation framework: minimum set of 10 core indicators to monitor and evaluate the health sector response to viral hepatitis B and C along the result chain in countries

Table 1: Targets of the WHO Global Health Sector Strategy on viral hepatitis, 2016–2021

Table 2: Summary of indicators for monitoring and evaluation of viral hepatitis B and C

Table 3: Metadata tables for each of the 10 core indicators for viral hepatitis B and C

Table 4: List and metadata of additional indicators specific to viral hepatitis B and C

Table 5: List and metadata of additional indicators for viral hepatitis B and C already formulated and/or collected through other programmes or national health system

ACKNOWLEDGEMENTS

Writing committee

Isabel Bergeri and Yvan Hutin (WHO Geneva)

WHO headquarters, regional offices and country offices, and International Agency for Research on Cancer (IARC)

WHO Global Hepatitis Programme team, Geneva: Stefan Wiktor, Yvan Hutin, Hande Harmanci, Isabel Bergeri

WHO Geneva: Karen Hennessey, Benedetta Allegranzi, Arshad Altaf, Bassim Zayed, Selma Khamassi, Junping Yu, Nicolas Clark

WHO Regional Office for the Western Pacific: Nick Walsh, Linh-vi Le, Eric Wiesen

WHO Regional Office for the Americas: Monica Alonso Gonzalez

WHO Regional Office for Europe: Antons Mozalevskis, Annemarie Stengaard

WHO Regional Office for South-East Asia: Dongbao Yu

WHO Regional Office for the Eastern Mediterranean: Matti Parry, Hamida Khattabi, Mondher Letaief

WHO Country Office China: Po-Lin Chan

WHO Country Office Viet Nam: Amitabh Suthar

IARC: Jacques Ferlay, Iacopo Baussano

Reviews were also provided by:

Rosmawati Mohamed (Asian-Pacific Association for the Study of the Liver, Malaysian Society of Gastroenterology and Hepatology, Malaysia)

Janus Ong (Hepatology Society of the Philippines, the Philippines)

John Ward (United States Centers for Disease Control and Prevention)

Representatives of civil society reference groups: Isabelle Meyer-Andrieux (MSF Switzerland), Samuel So (Asian Liver Center, Stanford University School of Medicine, USA)

Technical editing and layout

Leitmotif company (editing), Blossom company (layout)

Financial acknowledgement

The development of these guidelines was financially supported by the French Ministry of Foreign Affairs and United States Centers for Disease Control and Prevention.

ABBREVIATIONS AND ACRONYMS

Ag	antigen
ANC	antenatal care
anti-HAV	antibody against hepatitis A virus
anti-HBc	antibody against hepatitis B core antigen
anti-HCV	antibody against hepatitis C virus
anti-HDV	antibody against hepatitis D virus
anti-HEV	antibody against hepatitis E virus
CRVS	civil registration and vital statistics
DAA	direct-acting antiviral (drug)
DBS	dried blood spot
DHS	Demographic and Health Survey
DNA	deoxyribonucleic acid
EIA	enzyme immunoassay
EML	Essential Medicines List
EPI	Expanded Programme on Immunization
GHSS	WHO Global Health Sector Strategy (on viral hepatitis)
HAV	hepatitis A virus
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HCW	health-care worker
HDV	hepatitis D virus
HepB_BD	hepatitis B birth-dose vaccination in newborns (within first 24 hours of life)
HepB3	hepatitis B vaccination with 3 doses in infants
HEV	hepatitis E virus
HIV	human immunodeficiency virus
IARC	International Agency for Research on Cancer
ICD-10	International Statistical Classification of Diseases and Related Health Problems, tenth revision
IHP+	International Health Partnership
IPC	infection prevention and control
M&E	monitoring and evaluation
MICS	Multiple Indicator Cluster Survey
MSM	men who have sex with men

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27046

